Adele Woodhouse

Dr. Adele Woodhouse


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Experimental Neurology
Verified
Journal Article
Closed access
AKAnna E. King
Anna E. King
AWAdele Woodhouse
Adele Woodhouse
MKMatthew T.K. Kirkcaldie
Matthew T.K. Kirkcaldie
JVJames C. Vickers
James C. Vickers

8 February 2012 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JAJulien Amendola
Julien Amendola
AWAdele Woodhouse
Adele Woodhouse
MMMarie-France Martin-Eauclaire
Marie-France Martin-Eauclaire
JGJean-Marc Goaillard
Jean-Marc Goaillard
The level of expression of ion channels has been demonstrated to vary over a threefold to fourfold range from neuron to neuron, although the expression of distinct channels may be strongly correlated in the same neurons. We demonstrate that variability and covariation also apply to the biophysical properties of ion channels. We show that, in rat substantia nigra pars compacta dopaminergic neurons, the voltage dependences of the A-type (IA) and H-type (IH) currents exhibit a high degree of cell-to-cell variability, although they are strongly correlated in these cells. Our data also demonstrate that this cell-to-cell covariability of voltage dependences is sensitive to cytosolic cAMP and calcium levels. Finally, using dynamic clamp, we demonstrate that covaryingIAandIHvoltage dependences increases the dynamic range of rebound firing while covarying their amplitudes has a homeostatic effect on rebound firing. We propose that the covariation of voltage dependences of ion channels represents a flexible and energy-efficient way of tuning firing in neurons.

12 February 2016 in Current Alzheimer Research
Verified
Journal Article
Open access
JVJames C. Vickers
James C. Vickers
SMStan Mitew
Stan Mitew
AWAdele Woodhouse
Adele Woodhouse
CFCarmen M. Fernandez-Martos
Carmen M. Fernandez-Martos
MKMathew T. Kirkcaldie
Mathew T. Kirkcaldie
AKAnna E. King
Anna E. King
The prospects for effectively treating well-established dementia, such as Alzheimer’s disease (AD), are slim, due to the destruction of key brain pathways that underlie higher cognitive function. There has been a substantial shift in the field towards detecting conditions such as AD in their earliest stages, which would allow preventative or therapeutic approaches to substantially reduce risk and/or slow the progression of disease. AD is characterized by hallmark pathological changes such as extracellular Aß plaques and intracellular neurofibrillary pathology, which selectively affect specific subclasses of neurons and brain circuits. Current evidence indicates that Aß plaques begin to form many years before overt dementia, a gradual and progressive pathologywhich offers a potential target for early intervention. Early Aß changes in the brain result in localized damage to dendrites, axonal processes and synapses, to which excitatory synapses and the processes of projection neurons are highly vulnerable. Aß pathology is replicated in a range of transgenic models overexpressing mutant human familial AD genes (eg APP and presenilin 1). Studying the development of aberrant regenerative and degenerative changes in neuritic processes associated with Aß plaques may represent the best opportunity to understand the relationship between the pathological hallmarks of AD and neuronal damage, and to develop early interventions to prevent, slow down or mitigate against Aß pathology and/or the neuronal alterations that leads to cognitive impairment.

1 May 2004 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
RCRoger Chung
Roger Chung
AWAdele Woodhouse
Adele Woodhouse
SFS. Fung
S. Fung
TDTracey Dickson
Tracey Dickson
AWA. K. West
A. K. West
MCM. I. Chuah
M. I. Chuah

10 April 2014 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
MDMartial A. Dufour
Martial A. Dufour
AWAdele Woodhouse
Adele Woodhouse
JGJean‐Marc Goaillard
Jean‐Marc Goaillard

11 August 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RCRoger Chung
Roger Chung
CHClaire Howells
Claire Howells
EEEmma D. Eaton
Emma D. Eaton
LSLana Shabala
Lana Shabala
KZKairit Zovo
Kairit Zovo
AWAdrian K. West
Adrian K. West
A major pathological hallmark of AD is the deposition of insoluble extracellular β-amyloid (Aβ) plaques. There are compelling data suggesting that Aβ aggregation is catalysed by reaction with the metals zinc and copper. We now report that the major human-expressed metallothionein (MT) subtype, MT-2A, is capable of preventing the in vitro copper-mediated aggregation of Aβ1–40 and Aβ1–42. This action of MT-2A appears to involve a metal-swap between Zn7MT-2A and Cu(II)-Aβ, since neither Cu10MT-2A or carboxymethylated MT-2A blocked Cu(II)-Aβ aggregation. Furthermore, Zn7MT-2A blocked Cu(II)-Aβ induced changes in ionic homeostasis and subsequent neurotoxicity of cultured cortical neurons. These results indicate that MTs of the type represented by MT-2A are capable of protecting against Aβ aggregation and toxicity. Given the recent interest in metal-chelation therapies for AD that remove metal from Aβ leaving a metal-free Aβ that can readily bind metals again, we believe that MT-2A might represent a different therapeutic approach as the metal exchange between MT and Aβ leaves the Aβ in a Zn-bound, relatively inert form.